BridgeBio Pharma BBIO Interest Income
Interest Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's interest income?
- BridgeBio Pharma (BBIO) reported interest income of $6.25M in Q1 2026.
- How has BridgeBio Pharma's interest income changed year-over-year?
- BridgeBio Pharma's interest income increased by 16.0% year-over-year, from $5.39M to $6.25M.
- What is the long-term trend for BridgeBio Pharma's interest income?
- Over 4 years (2021 to 2025), BridgeBio Pharma's interest income has grown at a 104.6% compound annual growth rate (CAGR), from $1.13M to $19.85M.
- What does interest income mean?
- Money earned from interest on cash holdings and investments.
- How do you interpret interest income?
- Higher interest income indicates a larger cash balance or a more effective treasury management strategy.
- How does interest income compare across companies?
- Standard across all companies with significant cash balances; highly dependent on prevailing interest rates.